Indeed, over-correction of hERG resurgent current during the action potential is a significant limiting concern in the development of hERG activator compounds that target inactivation gating, since they may predispose to short QT syndrome (Vandenberg et al., 2012). The gene discussed is KCNH2; the disease is Familial short QT syndrome.